Navigation Links
Aratana Therapeutics Announces $20 Million Financing
Date:1/7/2011

KANSAS CITY, Kan., Jan. 7, 2011 /PRNewswire/ -- Aratana Therapeutics, a newly-formed company focused on the development of innovative therapies for the animal health industry, today announced that it has closed a $20 million Series A financing led by MPM Capital and Avalon Ventures.

"At Aratana, we will be focused on taking advancements from the human biopharmaceutical industry and applying them in new ways to treat and care for animals," said Dr. David Rosen, President and Founder of Aratana Therapeutics. "The addition of Dr. Linda Rhodes as CEO and the closing of the $20 million in financing are two major milestones that set Aratana up for future success moving forward."  

Dr. Linda Rhodes, a recognized leader in the fields of human and animal drug discovery and development, will join Aratana in February 2011 as Chief Executive Officer. Previously, Dr. Rhodes was founder and vice-president of clinical development at AlcheraBio, an entrepreneurial contract research organization devoted to helping major animal health companies develop new drugs.

"My entire career has been devoted to developing therapies for animals, and I am looking forward to continuing that work in this exciting, venture-capital model at Aratana," said Dr. Rhodes.

"Drs. Rhodes and Rosen are the perfect duo to execute the vision we have for Aratana," said Dr. Steven St. Peter, Managing Director at MPM Capital.  "Both are veterinarians, one with extensive drug development expertise and the other with extensive business development expertise."

Aratana's board of directors will include Dr. Rhodes; Dr. Steven St. Peter, Managing Director at MPM Capital; Jay Lichter, Managing Director at Avalon Ventures; and Ron Meeusen, Founder of Cultivian Ventures. Other investors in the round of financing include the Kansas Bioscience Authority.


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
6. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Arno Therapeutics Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Terascala, the ... announced that Alan Swahn, a former vice president of ... team as vice president of marketing. Terascala’s software when ... and NetApp create the highest performance and most reliable ... appointed to guide Terascala’s channel expansion and broaden its ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and exhibition ... at Double Tree by Hilton Beijing, China is all ... & Bioanalytical research methods only to facilitate improved living ... Dr. Srinubabu Gedela, MD of OMICS Group Inc has ... one in bringing a unique and international mix of ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... BioCryst,Pharmaceuticals (Nasdaq: BCRX ) today announced ... Chief Medical Officer of BioCryst, effective July 1,2008. ... recently,serving as Vice President of North American Medical ... Officer Dr. Tom Simon, who has been with,the ...
... use Nuevolution,s Chemetics(R) Technology for Lead Discovery, ... it has entered into a drug discovery collaboration ... its proprietary Chemetics(R) drug discovery,technology to identify novel ... to Merck. The Chemetics(R) platform uses innovative DNA,labeling ...
... Pa., June 17 MEDRAD, INC., announced ... a new Fluorodeoxyglucose (FDG),Infusion System for Positron ... Intego(TM) PET Infusion System is the,first infusion ... automate the FDG,delivery process., (Logo: ...
Cached Biology Technology:William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 2William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 3William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 4Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc. 2MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 2MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 3
(Date:7/11/2014)... Shenzhen, July 10, 2014---A team of researchers from The ... have identified a gene of wild soybean linked to ... to grow in saline soil. This study published online ... to unveil novel genomic information for crop improvement. , ... to domestication and human selection, cultivated soybeans have less ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... other group members to reduce aggression and gain access ... for grooming activities shows a certain pattern across the ... journal Biology Letters . , Grooming between individuals ... ulterior motives. To be groomed has hygienic benefits and ... individual can provide access to infants, mating opportunities and ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A new genome editing method brings the possibility of gene therapies closer to reality 2Baboons groom early in the day to get benefits later 2
... to Josef Ackermann, the head of Deutsche Bank. At almost ... in Rome. The hand of the manager in charge of ... or security staff have had to conduct painstaking inspections of ... approach. At the end of 2011, though, the scanner T-Cognition ...
... release is available in German . ... from Siegen and Professor Jacek Błażewicz from Poznan have ... (DFG, German Research Foundation) and the Foundation for Polish ... scientific collaboration. "The two researchers perform outstanding research, are ...
... groundbreaking new gene sequencing technology, researchers have demonstrated that ... Acute Myeloid Leukemia, AML, one of the most common ... Pacific Biosciences, allows for the rapid and comprehensive detection ... findings, published online April 15 in Nature , ...
Cached Biology News:On the safe side: Contact-free analysis of chemical substances 2Copernicus Award 2012 for German-Polish collaboration in business information systems 2Copernicus Award 2012 for German-Polish collaboration in business information systems 3Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia 2
... product contains 5 ml Dynabeads Tosylactivated (4.5 ... (tosyl) reactive groups. For coupling of antibodies ... on initial coupling with covalent binding of ... sulphydryll groups (SH)) occurringovernight. Coupling reactions can ...
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
... II inhibitor (IC50 = 59.2 M). ... H 32 O 13 MolWeight: ... RT CAS: ... Soluble to 100 mM in DMSO ...
NAP-2 (5C7)...
Biology Products: